Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest

Apollomics, Inc. (NASDAQ:APLMW) was the target of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 4,400 shares, a decrease of 38.9% from the January 31st total of 7,200 shares. Based on an average daily volume of 64,200 shares, the short-interest ratio is presently 0.1 days.

Apollomics Stock Performance

Shares of NASDAQ APLMW opened at $0.01 on Friday. The firm has a fifty day simple moving average of $0.01 and a two-hundred day simple moving average of $0.01. Apollomics has a 12 month low of $0.01 and a 12 month high of $0.04.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.